What is the role of a therapeutic trial of immunosuppressants in IRE?

• A. If disease persists after diet and antibiotic trials, immunosuppressants are started to control inflammation and prevent progression.
• B. Immunosuppressants are first-line regardless of response.
• C. Immunosuppressants have no role.
• D. Only used if there is infection.

Answer: (A)

The idea being tested is how immunosuppressants fit into the treatment sequence for immune-mediated intestinal disease. Start with dietary modification and antibiotics to identify and manage dietary-responsive or antibiotic-responsive enteropathies. If signs persist despite those trials, the next step is to introduce immunosuppressants to dampen the immune-driven inflammation. This approach helps to reduce mucosal inflammation and prevent long-term damage while avoiding unnecessary immunosuppression early on. Immunosuppressants aren’t first-line because you want to rule out infectious causes and minimize exposure to immune-modifying drugs unless the disease remains after initial, less risky therapies. If an infection were present, immunosuppression could worsen it, so infections must be ruled out before starting these agents. This makes the statement about starting immunosuppressants after diet and antibiotic trials, to control inflammation and prevent progression, the best description of their role.